Evidence map›Paper›PMID 35043375›Full record

ReviewNeurotoxicity research2022

Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.

Mohamed A Eldeeb, Mohamed A Ragheb, Marwa H Soliman, Richard P Fahlman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurotoxicity research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Molecular insights into NLRP1 Gly/N-degron recognition by CRL2Acta crystallographica. Section F, Structural biology communications · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Mohamed A EldeebChemistry Department (Biochemistry Division), Faculty of Science, Cairo University, Giza, Egypt. Mohamed.eldeeb@mcgill.ca.ORCID http://orcid.org/0000-0001-9671-9340
Mohamed A RaghebChemistry Department (Biochemistry Division), Faculty of Science, Cairo University, Giza, Egypt.
Marwa H SolimanChemistry Department (Biochemistry Division), Faculty of Science, Cairo University, Giza, Egypt.
Richard P FahlmanDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Cairo University · EGMontreal Neurological Institute and Hospital · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the most salient features that underpin the development of aging-related neurodegenerative disorders are the accumulation of protein aggregates and the decrease in cellular degradation capacity. Mammalian cells have evolved sophisticated quality control mechanisms to repair or eliminate the otherwise abnormal or misfolded proteins. Chaperones identify unstable or abnormal conformations in proteins and often help them regain their correct conformation. However, if repair is not an option, abnormal proteins are selectively degraded to prevent undesired interactions with other proteins or oligomerization into toxic multimeric complexes. The autophagic-lysosomal system and the ubiquitin-proteasome system mediate the selective and targeted degradation of abnormal or aberrant protein fragments. Despite an increasing understanding regarding the molecular responses that counteract the formation and clearance of dysfunctional protein aggregates, the role of N-degrons in these processes is poorly understood. Previous work demonstrated that the Arg-N-end rule degradation pathway (Arg-N-degron pathway) mediates the degradation of neurodegeneration-associated proteins, thereby regulating crucial signaling hubs that modulate the progression of neurodegenerative diseases. Herein, we discuss the functional interconnection between N-degron pathways and proteins associated with neurodegenerative disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. We also highlight some future prospects related to how the molecular insights gained from these processes will help unveil novel therapeutic approaches.

Indexed as

Neurodegenerative DiseasesUbiquitinAnimalsMammalsMolecular ChaperonesProteasome Endopeptidase ComplexProteolysisMolecular ChaperonesProteasome Endopeptidase ComplexUbiquitinN-degronN-end ruleParkinParkinson’s diseasePINK1ProteasomeProtein degradationSynucleinopathies; AβUbiquitin; Tau

Identifiers

PMID35043375
OpenAlexW4206672430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.